Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : DVAX save search
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Published: 2024-04-24 (Crawled : 20:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
| Email alert
Add to watchlist
first conference report financial results
MannKind Announces CFO Transition
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
SUPN | $30.26 1.04% 1.02% 200K
|
Health Technology
|
| O: 1.14%
H: 2.95%
C: 2.71%
MNKD | $4.19 0.72% 0.72% 2.2M
|
Health Technology
|
| O: -0.2%
H: 0.2%
C: -5.51%
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: -0.56%
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Published: 2024-02-27 (Crawled : 00:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.77%
H: 1.51%
C: 0.47%
conference health care
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
Published: 2024-02-22 (Crawled : 21:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.24%
H: 4.73%
C: 2.25%
year financial results
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
Published: 2024-02-08 (Crawled : 00:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.31%
H: 0.62%
C: 0.16%
conference report year financial results
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
Published: 2024-01-08 (Crawled : 16:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -4.9%
year financial
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
VERA | $39.95 1.09% 1.05% 770K
|
Professional, Scientific, and T...
|
| O: 0.58%
H: 17.29%
C: 16.07%
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -4.9%
medical therapeutics
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 00:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.97%
H: 3.09%
C: 2.88%
conference
Uvax Bio to give a Preclinical Development Update on its HIV-1 Vaccine at the World Vaccine Congress – West Coast 2023
Published: 2023-11-28 (Crawled : 16:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.14%
west vaccine congress world update preclinical
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
Published: 2023-11-20 (Crawled : 22:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.8%
H: 1.33%
C: -0.15%
conference
Global HBV Vaccine Market Set to Reach $2.47 Billion by 2023, Driven by Rising HBV Cases Among Infants
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
vaccine reach global set market
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Published: 2023-10-19 (Crawled : 23:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.07%
H: 0.41%
C: -1.86%
hepatitis conference virus
Vaccines Market Size To Reach USD 153.49 Billion, With at a 14.1% CAGR between 2022 to 2028 | Brandessence Market Research
Published: 2023-09-26 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
ALPMY | News | $9.47 -0.21% -1.11% 20K
|
Manufacturing
|
| O: -4.29%
H: 5.93%
C: 2.89%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.35%
H: 2.48%
C: 0.71%
reach research market
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-09-06 (Crawled : 20:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: -0.65%
conference global
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Published: 2023-08-03 (Crawled : 22:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.44%
H: 1.74%
C: -0.67%
year financial results
Global Cancer Vaccine Industry Worth $13.4 Billion by 2030: Use of Nanosensors in Diagnosing Cancer Expected to Create Ample Opportunities for Key Players
Published: 2023-06-27 (Crawled : 10:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
MRNA | News S | $108.85 0.89% 0.85% 3M
|
Health Technology
|
| O: 0.03%
H: 0.37%
C: 0.18%
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.08%
H: 1.31%
C: 0.77%
vaccine expected cancer global
Dynavax Reports First Quarter 2023 Financial Results
Published: 2023-05-02 (Crawled : 20:00) - prnewswire.com
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -2.42%
H: 11.33%
C: 9.54%
financial results
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
Published: 2023-04-18 (Crawled : 01:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: 0.53%
H: 0.18%
C: -2.39%
conference report financial results
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Published: 2023-03-02 (Crawled : 08:00) - biospace.com/
DVAX | $11.42 -2.89% -2.98% 59K
|
Health Technology
|
| O: -0.88%
H: 1.29%
C: 0.79%
covid-19 valneva vaccine vla2001
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.